Genitourinary Cancers Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
genitourinary cancers clinical trials:
A study for patients with Metastatic Castration Resistant Prostate Cancer
(mCRPC) (CAPItello-280)
Treatment agent: Capivasertib + docetaxel vs placebo + docetaxel
Physician:
Wes Lee, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for
Metastatic Castration Resistant Prostate Cancer (mCRPC) - Full Text View
- ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA
NRG-GU010 Guidance Study Phase III Randomized Trial of Genomic-Risk Stratified
Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And
Intensification Clinical Trial Evaluation
Treatment agent: Radiotherapy +/- Androgen Deprivation Therapy (ADT)
Physician:
Michael N. Corradetti
Study Coordinator: Beatrice Becker //
beatrice.becker@providence.org // 707-932-5164
Study Resources:
https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Queen of the Valley Medical Center, Napa, CA
A study for patients with hisk risk non muscle invasive bladder cancer
Treatment agent: TAR-200 in Combination with Cetrelimab or TAR-200 Alone
Versus Intravesical Bacillus Calmette-Guerin (BCG)
Physician:
YaoYao Pollock, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus
Intravesical Bacillus Calmette-Guérin (BCG) in Participants With
BCG-naïve High-risk Non-muscle Invasive Bladder Cancer - Full Text
View - ClinicalTrials.gov
Sponsor: Janssen Research and Development, LLC
Location: Providence Cancer Center Santa Rosa, CA
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin
in Combination with Pembrolizumab Versus Chemotherapy in Subjects with
Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
that Expresses HER2 (SGNDV-001/KN-D74)
Treatment agent: Disitamab Vedotin + Pembrolizumab vs Chemotherapy
Physician:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT05911295
Sponsor: SeaGen Biotech
Location: Providence Cancer Center Santa Rosa, CA